Navigation Links
GeneLink Announces HelixLife Private Label Distribution Agreement
Date:9/24/2010

ORLANDO, Fla., Sept. 24 /PRNewswire/ -- GeneLink BioSciences, Inc. (OTC Bulletin Board: GNLK, www.genelinkbio.com) today announced the launch of HelixLife, (www.helixlife.com), a private label distribution partnership serving the healthcare and wellness industries.

Gary Beeman, GeneLink CEO, stated, "HelixLife gives GeneLink reach into new areas of the rapidly expanding personalized wellness markets that previously have not been available to us.  The HelixLife team is very experienced and will expand the visibility and healthcare market penetration of our 'Powered by GeneLink' technologies and our unique genetically-guided nutritional and skin care products."  

Brad Rex, HelixLife CEO added, "We are excited to showcase GeneLink's 16 years of incredible DNA research and product development with the HelixLife product line of anti-aging nutritional supplements and skin serums, youth supplements and anti-acne products.  We look forward to working together to optimize our customer's health, appearance and well being."

The HelixLife product line includes:  

HelixLife brilliant™ custom DNA nutritional adult supplements and anti-aging skin serum formulated and manufactured to each customer's specific genetic profile,

HelixLife assess™ DNA nutritional and skin assessment test,

HelixLife bright™ full-spectrum adult foundational supplements,

HelixLife grow™ nutritional supplements custom-designed for youth ages 11-17,

HelixLife glow™ natural and organic anti-aging skin serum,

HelixLife clear™ non-chemical based anti-acne skin serum, and

HelixLife active™ chocolate-based energy chews, a healthy alternative to energy drinks

HelixLife products are manufactured in the USA from the highest quality, freshest ingredients, and are shipped directly from production to customer, not warehouse-stored.  For more information, go to www.helixlife.com.

About GeneLink BioSciences, Inc.  

GeneLink is a genomics, biotechnology, and wellness company engaged in genetic test development, product development, and manufacturing of personalized wellness products.  GeneLink's patented and proprietary technologies include genetic assessments focused on the delivery of personally customized and manufactured nutritional supplements and skin care products for health, beauty and wellness applications. For additional information, please visit www.genelinkbio.com.

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.



'/>"/>
SOURCE GeneLink BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. GeneLink Reports First Quarter Gains
2. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
3. SCARGUARD LABS, LLC Announces Key Consumption Results Fastest Growing Brand and Second in Total Rankings
4. PAREXEL Announces Date of First Quarter Fiscal Year 2011 Earnings Release and Conference Call
5. Advanced Targeting Systems, Inc. Announces $3 Million Award from National Cancer Institute
6. Genesis Biopharma Announces $700K Private Financing
7. S*BIO Announces US$5 Million Investment by Mitsui Ventures
8. Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
9. TOPICA Pharmaceuticals Announces Sublicensing Agreement for Tinea Indication
10. Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation
11. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/25/2017)... ... February 25, 2017 , ... ... Trials in an ongoing effort to create meaningful change by increasing communication, ... research with emphasis on consumers and patients’ mental health well-being. , Both organizations ...
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company ... National Institute of Mental Health (NIMH) for the further advancement of the company’s 3-month ... technology and is expected to deliver therapeutic levels of olanzapine for a period of ...
(Date:2/24/2017)... 24, 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: ... a clinical-stage oncology and dermatology biopharmaceutical company, today ... participate in its previously announced rights offering of ... of common stock and Series C Convertible Preferred ... warrants. As previously announced, the ...
(Date:2/24/2017)... Symic Bio, a biopharmaceutical company focused on ... therapeutics, announced today the completion of enrollment for the ... The trial will evaluate the safety and efficacy of ... of restenosis following angioplasty. "We,re pleased ... said Nathan Bachtell , M.D., Chief Medical Officer ...
Breaking Biology Technology:
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... , its innovative, highly flexible and award winning eClinical ... customers. iMedNet is a proven Software-as-a-Service (SaaS) ... Data Capture (EDC), but also delivers an entire suite ...
(Date:2/3/2017)... -- A new independent identity strategy consultancy firm announces ... Designed to fill a critical niche in technical and ... Mark Crego and Janice Kephart ... expertise that span federal governments, the 9/11 Commission, private ... expertise has a common theme born from a shared ...
(Date:1/31/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded ... bacterial infections, today announced it has acquired a ... Bono Bio Ltd (PBB) to bolster its pipeline ... of Gram-negative bacteria.   The assets acquired have been ... group company. "The acquisition of these ...
Breaking Biology News(10 mins):